Who are Elidel-Creme's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pimecrolimus active cream, topical pimecrolimus treatment, Pimecrolimus Cream 1%, Elidel (pimecrolimus 1%), Elidel® (pimecrolimus) Cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elidel-creme.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Elidel-Creme — Competitive Intelligence Brief

Elidel-Creme (Elidel-Creme) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor (topical immunosuppressant). Area: Dermatology/Immunology.

marketed Calcineurin inhibitor (topical immunosuppressant) Calcineurin; macrophilin-12 Dermatology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Elidel-Creme (Elidel-Creme) — Technische Universität Dresden. Elidel (pimecrolimus) is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Elidel-Creme TARGET	Elidel-Creme	Technische Universität Dresden	marketed	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin; macrophilin-12
pimecrolimus active cream	pimecrolimus active cream	Children's Hospital of Michigan	marketed	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin (protein phosphatase 2B)
topical pimecrolimus treatment	topical pimecrolimus treatment	University Hospital, Ghent	marketed	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin
Pimecrolimus Cream 1%	Pimecrolimus Cream 1%	Novartis	marketed	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin (protein phosphatase 2B)
Elidel (pimecrolimus 1%)	Elidel (pimecrolimus 1%)	St Joseph University, Beirut, Lebanon	phase 3	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin (protein phosphatase 2B)
Elidel® (pimecrolimus) Cream	Elidel® (pimecrolimus) Cream	Glenmark Pharmaceuticals Ltd. India	phase 3	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin (via macrophilin-12 binding)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcineurin inhibitor (topical immunosuppressant) class)

Children's Hospital of Michigan · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
Novartis · 1 drug in this class
St Joseph University, Beirut, Lebanon · 1 drug in this class
Technische Universität Dresden · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elidel-Creme — Competitive Intelligence Brief. https://druglandscape.com/ci/elidel-creme. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab